Evidence map›Paper›PMID 28698140›Full record

ArticleBiochemical and biophysical research communications2017

N-arachidonoyl glycine, another endogenous agonist of GPR55.

Linda Console-Bram, Sandra M Ciuciu, Pingwei Zhao, Robert E Zipkin, Eugen Brailoiu, Mary E Abood

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Receptor-Dependent and Independent Regulation of Voltage-Gated CaInternational journal of molecular sciences · 2021
    Review
  6. Review
  7. Review
  8. Crosstalk between the MCellular signalling · 2020
    Review
  9. Biomolecules · 2019
    Review
  10. Review
  11. Article
  12. Ablation of PM20D1 revealsProceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  13. ΔBiochimica et biophysica acta. Molecular and cell biology of lipids · 2018
    Article
  14. Review
  15. Article
  16. Journal of biology and nature · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linda Console-BramCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 N. Broad St., Philadelphia, PA, 19140, USA. Electronic address: lindacb@temple.edu.
Sandra M CiuciuCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 N. Broad St., Philadelphia, PA, 19140, USA. Electronic address: alexandra.ciuciu@temple.edu.
Pingwei ZhaoCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 N. Broad St., Philadelphia, PA, 19140, USA. Electronic address: zhaopw@temple.edu.
Robert E ZipkinFocus Biomolecules, 400 Davis Drive #600, Plymouth Meeting, PA, 19462, USA. Electronic address: rzipkin@focusbiomolecules.com.
Eugen BrailoiuCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 N. Broad St., Philadelphia, PA, 19140, USA. Electronic address: ebrailou@temple.edu.
Mary E AboodCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 N. Broad St., Philadelphia, PA, 19140, USA. Electronic address: mabood@temple.edu.

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Munir Gunes Kutlu · 2000 to 2026
$34.6M
Molecular Characterization of GPR35 and GPR55, Putative Cannabinoid ReceptorsR01DA023204 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ABOOD, MARY E · 2007 to 2016
$3.2M
Functional Role for GPR55 in the periaqueductal grayR01DA035926 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ABOOD, MARY E, BENAMAR, KHALID · 2014 to 2018
$1.6M
NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA023204NIDA NIH HHS R01 DA035926
6 · The paper itself

Abstract

Interest in lipoamino acids as endogenous modulators of G-protein coupled receptors has escalated due to their involvement in a variety of physiologic processes. In particular, a role for these amino acid conjugates has emerged in the endocannabinoid system. The study presented herein investigated the effects of N-arachidonoyl glycine (NAGly) on a candidate endocannabinoid receptor, GPR55. Our novel findings reveal that NAGly induces concentration dependent increases in calcium mobilization and mitogen-activated protein kinase activities in HAGPR55/CHO cells. These increases were attenuated by the selective GPR55 antagonist ML193 (N-[4-[[(3,4-Dimethyl-5-isoxazolyl)amino]sulfonyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide), supporting receptor mediated signaling. To our knowledge this is the first report identifying GPR55 as a target of the endogenous lipoamino acid, NAGly.

Indexed as

AnimalsArachidonic AcidsCalciumCHO CellsCricetulusDose-Response Relationship, DrugGene Expression RegulationGlycineHumansInositol 1,4,5-Trisphosphate ReceptorsKineticsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3QuinolinesReceptors, CannabinoidReceptors, G-Protein-CoupledArachidonic AcidsCalciumGlycineGPR55 protein, humanInositol 1,4,5-Trisphosphate ReceptorsMAPK1 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3N-arachidonylglycineQuinolinesReceptors, CannabinoidReceptors, G-Protein-CoupledBafilomycin A1 (PubChem CID 6436223)CalciumGPR55Inositol-3-phosphate receptorMitogen activated protein kinaseML193, (N-[4-[[(3,4-Dimethyl-5-isoxazolyl)amino]sulfonyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide) (PubChem CID1261822)N-arachidonyl glycineN-arachidonyl glycine (PubChem CID 5283389)ryanodine (PubChem CID 11317883)Xestopongin C (PubChem CID 9846431)

Identifiers

PMID28698140
PMCPMC5576593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.